首页> 外国专利> MATERIALS AND METHODS FOR MOBILIZING CELLS INCLUDING CD34+, HEMATOPOIETIC COLONY FORMING, AND ENDOTHELIAL COLONY FORMING CELLS

MATERIALS AND METHODS FOR MOBILIZING CELLS INCLUDING CD34+, HEMATOPOIETIC COLONY FORMING, AND ENDOTHELIAL COLONY FORMING CELLS

机译:用于移动细胞的材料和方法,包括CD34 +,造血性结肠形成和内皮细胞形成细胞

摘要

Disclosed herein are materials and methods such as the use of none steroidal anti-inflammatory drugs to increase the number of CD34+ cell in human patients. The level of ECFC measured in volunteers before and after treatment with meloxicam. Only 4/7 volunteers had detectable levels of ECFC in a 40 mL sample of peripheral of blood (PB) before treatment, while 7/7 had detectable levels of ECFC in a similar sample collected post-meloxicam treatment. Administering a course of treatment with NSAID also increased the number of endothelial colony forming cells (ECFC) in the volunteers PB and it reduced culture time to first ECFC detection. These data demonstrate that NSAID administration mobilizes both hematopoietic and endothelial progenitors to PB. This provides a safe and effective strategy that can be added to existing mobilization regimens and is especially useful when combined with a course of treatment that includes the use of G-CSF.
机译:本文公开的是材料和方法,例如不使用类固醇抗炎药来增加人类患者中CD34 +细胞的数量。美洛昔康治疗前后志愿者中测得的ECFC水平。治疗前,只有40/7的志愿者在40 mL外周血(PB)样​​品中可检测到ECFC水平,而类似的样品中7/7的患者在美洛昔康治疗后收集到的ECFC可检测水平。使用NSAID治疗一个疗程还增加了志愿者PB中的内皮集落形成细胞(ECFC)的数量,并且减少了首次检测ECFC的培养时间。这些数据表明,NSAID给药可将造血和内皮祖细胞动员为PB。这提供了一种安全有效的策略,可以将其添加到现有的动员方案中,并且在与包括使用G-CSF的治疗过程相结合时特别有用。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号